SONDAS DE ANTICUERPOS PARA PROTEÍNAS Detección de proteínas específicas mediante anticuerpos.
NIVELES DE ANTICUERPOS
-
Upload
rafael-leyva-huitron -
Category
Documents
-
view
219 -
download
0
Transcript of NIVELES DE ANTICUERPOS
-
8/3/2019 NIVELES DE ANTICUERPOS
1/10
Vaccine 24 (2006) 17761785
Immunogenicity and safety of four different doses ofHaemophilusinfluenzae type b-tetanus toxoid conjugated vaccine, combined with
diphtheriatetanuspertussis vaccine (DTP-Hib), in Indonesian infants
Narain H. Punjabi a,, Emily L. Richie a, Cyrus H. Simanjuntakb, Sri Juliani Harjanto a,Ferry Wangsasaputra a, Sumarjati Arjoso b, Ainur Rofiq b, Mulyati Prijanto b,
Julitasari c, Ursula Yela d, Christian Herzog d, Stanley J. Cryz e
a U.S. Naval Medical Research Unit No. 2, Jakarta, Indonesiab National Institute of Health Research and Development, Ministry of Health, R.I., Jakarta, Indonesia
c Communicable Disease Control, Ministry of Health, R.I., Jakarta, Indonesiad Berna Biotech Ltd., Berne, Switzerland
e Massachussetts Biologic Laboratories, University of Massachussetts Medical Center, Jamaica Plain, MA, USA.
Received 23 May 2005; received in revised form 30 September 2005; accepted 10 October 2005
Available online 27 October 2005
Abstract
Widespread use ofHaemophilus influenzae type b (Hib) conjugated vaccine in industrialized countries has resulted in a dramatic decline
in the incidence of invasive Hib diseases, but the vaccines cost has prevented its inclusion in basic immunization programs in developing
countries. To overcome this problem, combination with diphtheriatetanuspertussis (DTP) vaccine or reduction in the dose of Hib vaccine
has been proposed. To evaluate the immunogenicity and adverse reactions from lower doses of Hib-polyribosylphosphate (PRP) conjugated
with tetanus toxoid (PRP-T), a double-blind study was conducted in Jakarta, Indonesia, and its suburbs. A total of 1048 infants 6 weeks to 6
months of age received three doses of DTP vaccine combined with the usual 10 g dose or with a reduced dose of 5, 2.5 or 1.25 g of PRP-T
at two-monthly intervals. Antibodies were measured prior to the first dose and 46 weeks following the third dose. Adverse reactions were
similar among all four groups. The only significant difference was a higher rate of irritability (p < 0.02) and of temperature elevation >38 C
(p < 0.009) after doses 1 and 2 in the lowest dose group (1.25g PRP-T) compared to the other groups.
All participants tested had a 4-fold increase in antibodies against all DTP antigens. In addition, after a fourth booster dose of Hib, 99.6% of
infants produced 0.15g/ml of antibody to Hib-PRP, and 96.4% showed levels1.0g/ml after primary immunization, level that correlate
with short- and long-term immunity, respectively. Antibody titers to the PRP antigen showed no significant differences among dosage groups
with the exception of the 5.0 g group, which had a significantly higher GMC than the 1.25 g group (p < 0.012).
This study demonstrates that primary vaccination with half, one-fourth, or one-eighth of the usual dose of PRP-T, combined with DTP
vaccine, produces protective immune responses, and has side effects that are comparable to DTP vaccination alone. In these lower dosages,
PRP-T conjugate vaccine can lower vaccine costs to a level that is affordable for infant immunization programs in developing countries.
2005 Elsevier Ltd. All rights reserved.
Keywords: Haemophilus influenzae type b; Lower dose; DTP-Hib
Disclaimer: The views expressed in this paper are those of the authors
anddo notin any wayrepresentthoseof theUS Navyand theUS Department
of Defense as well the Indonesian Ministry of Health. Corresponding author.
E-mail address: [email protected] (N.H. Punjabi).
1. Introduction
It is estimated that of the 10 million annual deaths in
children less than 5 years of ageworldwide, 99% are in devel-
oping countries, and 70% are due to infectious diseases [1].
Pneumonia is the leading cause of early childhood death, and
0264-410X/$ see front matter 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.vaccine.2005.10.023
-
8/3/2019 NIVELES DE ANTICUERPOS
2/10
N.H. Punjabi et al. / Vaccine 24 (2006) 17761785 1777
meningitis is among the 10 most common causes of death
from infectious diseases among children under 5 years of
age in developing countries [2,3].
Haemophilus influenzae type b (Hib) used to be an impor-
tant cause of morbidity and mortality for children under age
5 in industrialized countries [4]. The incidence of invasive
disease due to Hib declined dramatically after the inclu-sion of Hib-conjugate vaccine in routine pediatric immuniza-
tion programs in these countries [49]. For various reasons,
principally insufficient data on the incidence of Hib inva-
sive diseases and vaccine cost, this practice has not been
adopted in developing countries [4,10,11]. Many microbi-
ology laboratories in developing countries have difficulty
isolating Hib bacteria, due to lack of technological expertise,
widespread use of antibiotics prior to culture, prioritizing
isolation of other microorganisms over Hib, and the cost of
testing [10,12]. As a result, disease incidence may be under-
reported in many Asian and African countries.
The success of Hib conjugate vaccines in Western nations
led to clinical trials and improvements in laboratory detec-tion of Hib pathogens in developing countries; incidences of
pneumonia and meningitis due to Hib were found to be simi-
lar to or higher than in industrialized countries [4,10,1315].
These studies show that disease occurs at earlier ages and is
associated with higher morbidity and mortality in less devel-
oped countries. However, few of these countries can afford
to include Hib vaccine in their Expanded Program of Immu-
nization (EPI). For example, a single dose of Hib vaccine or
a bacterial culture (cerebrospinal fluid or blood) would each
cost over US$ 10. This remains unaffordable for developing
world families whose monthly incomes are about US$ 30
[1618].Vaccine costs can be reduced through several strategies,
such as combinations with other vaccine(s), multi-dose vials,
and lowering the amounts of immunizing agents. Adminis-
tration of reduced doses of Hib in combination with DPT
produces protective antibody levels because of the adjuvant
effect of the whole cell pertussis component [4,1720].
The objective of this study was to evaluate the immuno-
genicity and safety of primary immunization with three lower
doses of PRP-T (5, 2.5, or 1.25 g) combined with DTP
(whole cell killed pertussis), compared to DTP combined
with the standard Hib dose (10 g), in Indonesian infants.
2. Materials and methods
2.1. Study participants
The mothers of infants aged 6 weeks to 6 months at seven
community health centers (CHCs, also called PUSKESMAS)
in Jakarta and surrounding areas were offered to have their
infant participate in the study. The study purpose, risks, ben-
efits, and procedures were explained prior to enrollment, and
written informed consent was obtained from a parent prior to
enrollment.
Only healthy infants were enrolled. Eligibility was lim-
ited to infants who had no history of prior immunization
with any DTP or Hib vaccine (Hib vaccine is not yet avail-
able in these health centers), no history of neurological or
developmental disorders including seizure or febrile convul-
sions, no history of systemic illness, no history of treatment
with corticosteroids, immunosuppressants, blood products orinvestigational drugs, no evidence of immunodeficiency in
eitherthe infantor themother,no history of allergies, a normal
physical examination, weight >4 kg and axillary temperature
-
8/3/2019 NIVELES DE ANTICUERPOS
3/10
1778 N.H. Punjabi et al. / Vaccine 24 (2006) 17761785
pre-filled syringes that were labeled with a unique number
corresponding to the participants study number. Each 0.5 ml
dose contained 25 Lf of diphtheria toxoid, 5 Lf of tetanus tox-
oid, 5.8IU of inactivatedBordetellapertussis wholecells, and
one of four doses ofHaemophilus influenzae type b polyribo-
sylphosphate conjugated to tetanus toxoid (PRP-T), namely
10, 5,2.5, or1.25g. All syringes with pre-filled vaccine hadsimilar physical appearance and the cold chain was main-
tained from Switzerland until administration to the infant.
All vaccines were adsorbed to AlPO4, with the average
quantity of AlPO4 adjuvantper dose of being 2 mg/0.5 ml.For
primary immunization, only one batch of DTP with varying
dosages of PRP-T was used. Two different batches of DTP-
Hib vaccine were used for booster immunization.
2.3. Trial design
The study was conducted in a double-blind manner. All
infants who met all inclusion criteria were sequentially
assigned a unique study number, which was maintainedthroughout the primary and booster immunization studies.
The investigators, staff, and participants were not aware of
the composition of any infants vaccine. Vaccine was admin-
istered intramuscularly in the anterolateral thigh, alternating
right and left for each dose. Primary immunization consisted
of three doses of vaccine given at 79-week intervals; longer
intervals between vaccine doses occurred if inter-current ill-
ness or absence of the infant necessitated postponing vacci-
nation. Data analysis for immune responses excluded results
for infants whose vaccine doses were more than 12 weeks
apart. Infants were observed for at least 30 min after each
vaccination, and were released after being checked by a studyphysician.
Immunization was postponed for any febrile illness within
the preceding 24 h (axillary temperature >37.5 C), or for
significant inter-current illnesses such as otitis media, pneu-
monia, gastroenteritis, or severe malnutrition. Infants were
excluded from continued participation for any of the fol-
lowing events after previous immunization: febrile convul-
sion, seizure, encephalopathy, meningitis or other neurologi-
cal disorders, hypotonic/hyporesponsiveness or anaphylactic
episodes within 48 h of immunization, chronic systemic ill-
ness requiring regular medication, and persistent crying (>3 h
within 48 h of immunization). Venous blood samples were
obtained before immunization and 46 weeks after the third
vaccination. The serum was separated into tubes labeled with
the date and study number and then frozen at 70 C.
Parents and CHWs were instructed about possible side
effects, how to reach study doctors, and when to go to the
CHC or hospital if their infant was ill. Parents were asked
to complete an adverse reactions report form for 7 days
after each immunization, including measurement of daily
temperature. For this they were provided a thermometer
and instructed how to use it. A study physician reviewed
adverse events reported on the form and examined each
infant, recorded body temperature and examination results,
on days 1, 2 and either 5, 6, or 7 following each immu-
nization. The solicited specific symptoms and signs were
rated as either absent, mild, moderate or severe: irritability,
anorexia, seizure, hyporesponsivehypotonic episode, incon-
solable crying, vomiting and diarrhea. The diameter of ery-
thema and induration at the injection site were measured in
millimeters. Any inter-current illness was also evaluated andtreated.
Children who were excluded from further participation
were referred to their CHC for continuation of their immu-
nizations according to Indonesian Ministry of Health policy.
Data on demographics, adverse reactions, and immune
responses were double entered using EpiInfo in a blinded
manner. The randomization list was prepared at Berna
Biotech Ltd. Thevaccinecode was broken only after analyses
of both the safety and serological data were performed.
2.4. Serological assays
All serological assays were performed in a blinded man-ner. Total anti-PRP serum antibody was measured using a
Farr-type radioimmunoassay with intrinsically labeled 3H-
PRP supplied by the University of Rochester, Rochester,
NY, as previously described [19,20]. In summary: a con-
stant amount of 3H labeled PRP is reacted with dilutions
of a reference anti-PRP antibody solution or test sera to form
a soluble antibodyantigen complex. This complex is precip-
itated with 50% cold saturated ammonium sulfate solution.
The precipitated antibodyantigen complex is collected by
filtrationthrough a 0.45m filter. 36 Chlorine (36Cl)is added
to the reactant mixture as a control to determine the efficiency
of the filtration step. The amount of3
H radioactivity retainedby the filter corresponds to the amount of specific anti-PRP
presented in the reactant.
The results are expressed as micrograms of anti-PRP
antibody per milliliter of serum. A reference serum (cali-
brated against a standard supplied by the Center for Biologies
Evaluation and Research, Food and Drug Administration,
Bethesda, MD), anti-PRP solution, Nosocuman Lot 1, SSIV,
with an assigned value of 13.01g/ml. A protective antibody
concentration was assigned a value of >0.15 g IU/ml.
Anti-diphtheria toxin, anti-tetanus toxin, anti-pertussis
toxin and anti-FHA antibodies were examined by ELISA
method. Antigens used for coating ELISA were Tetanus Tox-
oid Lot 153, Berna Biotech AG, FHA Lot 702293, Berna
Biotech AG, Diphtheria Toxin, Lot 300-1, Berna Biotech
AG, Pertussis Toxin, Lot 0623P, Berna Biotech AG. The
secondary antibody which has been used is a peroxidase
labeled affinity purified goat anti-human IgG (Art. Nr. 074-
1002, Kirkegaard and Perry). Briefly, 100l of a 1g/ml
antigen solution in phosphate buffered saline (PBS) was
used to coat each microliter well (72 h, 4 C). The coating
solution was removed and the wells blocked with a casein
solution (2 mg/ml in PBS) for 1 h at 37 C. The plates were
then washed repeatedly with PBS containing 0.05% tween-
20 (PBS-T). To each well was added 100l of serum sample
-
8/3/2019 NIVELES DE ANTICUERPOS
4/10
N.H. Punjabi et al. / Vaccine 24 (2006) 17761785 1779
serially diluted in PBS-T containing 2 mg/ml casein (PBS-
T-C). After incubation for 3 h at ambient temperature, the
plateswere washed three times with PBS-T. Anti-human IgG,
(Kirkegaard and Perry, Gaithesberg, MD), diluted 1:2500
in PBS-T-C was added (100l per well). After incubation
for 2 h at 22 C, the wells were washed with PBS-T, 100 l
of ABTS substrate (Boehringer, Mannheim, Germany) wasadded and the color was allowed to develop for 30 min. A405was read on a Dynatech (Embach, Switzerland) MR5000
ELISA reader. A standard antiserum containing a known
amount of specific antibody was run in parallel and the values
of the test samples were determined. Antibodies to tetanus
and diphtheria toxins are expressed in international units
(IU) per milliliters. A protective titer was assigned a value
of0.1 IU/ml. Anti-pertussis toxin and anti-FHA antibody
levels are reported in micrograms per milliliter.
B. pertussis whole cell agglutinating antibody was deter-
mined as follows: Lyophilized B. pertussis strain 460 (200
US opacity units per milliliter) was reconstituted and diluted
1:10 in saline containing 0.01% (w/w) thimerosal to yieldan A530 of 1.21.4. Pre-diluted (50l at a 1:20 dilution) test
sera were serially diluted (2-fold) using saline in U-bottomed
micro titer plates. To each well was added 50loftheB. per-
tussis cell suspension and the plates were vigorously shaken
for 1 min using an MA69 Micro shaker (Cooke Microtiter
System, Dynatech, Embach, Switzerland). The plates were
then sheathed with plastic foil and incubated at 35 C for
approximately 18 h. The agglutin titer was defined as the
reciprocal of the highest serum dilution resulting in a thin
sheet of cells with a slight button. A human reference serum
was run in parallel. Theagglutinin titer is defined as the recip-
rocal of the highest serum dilution giving a thin sheet of cellswith slight button. The humanreference serumwas Tosuman
ZL, Berna Biotech AG. This was used as a control forthe test.
2.5. Statistical analysis
Differences between geometric mean concentrations
(GMCs) were determined using a two-tailed t-test on log-
transformed values. The differences between adverse events
associated with immunization among different groups of
Hib-PRP-T dosages were determined using ANOVA and
the non-parametric test KruskalWallis (H test). The values
of GMC were log-transformed and the differences between
groups attaining a given antibody level/geometric mean con-
centration (GMC) were also determined using ANOVA and
non-parametric test KruskalWallis (H test).
3. Results
The study was conducted over 3.5 years: primary immu-
nization from June 1996 through May 1999 and booster
immunization from September 1997 until January 2000. A
total of 1294 children were enrolled andreceivedthe first dose
of vaccine. Totals of 1146 (89%) and 1048 (81%) received
2nd and 3rd dose, and 608 children or 47% of those who
received the first dose of vaccine, received the 4th (booster)
doses, respectively. All of them had complete monitoring of
the side effects. Of the 1048 infants who completed primary
immunization, 1006 (96%) had blood drawn for serological
studies. The mean ages at the time of the first, second, third,
and booster doses were 96, 161, 227, and 548 days, respec-tively. There were no significant differences among vaccine
groups in mean ages or gender distribution at the time of any
of the three immunizations (Table 1). A total of 215 children
had serologic testing before booster immunization, and 184
had repeat testing after vaccination.
3.1. Immunogenicity
Immunogenicity data are presented for the primary vacci-
nation series; sera drawn before and after the booster doses
are pending upon serological testing; these results are to be
published subsequently.
3.1.1. Pre-immunization serology
Prior to vaccination, there were no significant differences
in geometric mean concentrations (GMCs) to vaccine anti-
gens among the groups, with the exception of filamentous
hemagglutinin antibody (FHA) titers in the Hib 1.25g
group: these were with 0.63g/ml, significantly higher than
the GMCsin the 2.5 and 5.0g groups (0.44 and 0.46g/ml,
respectively, p < 0.02). Similarly, protective antibody levels
pre-immunization showed significantly higher percentages of
infants with anti-tetanus toxoid levels of0.1 IU/ml in the
1.25g group (93%) versus the 10 g group (85%).
In the 1.25g group, however, a lower percentage ofinfants (32%) had pre-immunization anti-PRP-Hib levels
0.15g/ml than either the 5.0 or 10.0 g groups (45 and
43%; p < 0.05).
3.1.2. Post-immunization serology
Tables 2 and 4 present pre- and post-immunization GMC
data and the rate of infants achieving protective antibody lev-
els.
Immune responses to Hib antigen demonstrated a sig-
nificantly lower post-immunization anti-PRP GMC in the
1.25g group (12.48) than in the higher dose groups (15.62,
17.28, and 15.10) respectively;however,all infants developed
protective antibody levels. Similarly, primary immunization
generated high levels of anti-PRP antibody seroprotection
rates: 99.6100% reached 0.15g/ml, and 96.498.2%
reached 1.0g/ml. There were no significant differences
among the four Hib dosage groups (Table 4).
For anti-tetanus toxoid GMCs, the 2.5g Hib group
showeda significantlylower GMC(18.15) than in the1.25g
group (22.88). There were no significant differences in B.
pertussis agglutinating antibody GMCs. However, GMCs of
anti-pertussis toxin differed: the 1.25g group achieved a
significantly higher GMC (11.40) than the 2.5g (6.94),
5.0g (7.55) and 10g groups (8.64). In addition, the
-
8/3/2019 NIVELES DE ANTICUERPOS
5/10
1780 N.H. Punjabi et al. / Vaccine 24 (2006) 17761785
Table1
DemographiccharacteristicsofvaccinatedchildrenbydoseandHib-PRP-Tdosages
DoseI(N=1294)
DoseII(N=1146)
DoseIII(N=1057)
DoseIV(N=608)
1.2
5g
(N=190)
2.5g
(N=370)
5.0g
(N=367)
10.0
g
(N=367)
1.2
5g
(N=164)
2.5g
(N=328)
5.0g
(N=331)
10.0g
(N=323)
1.2
5g
(N=149)
2.5g
(N=303)
5.0g
(N=312)
10.0g
(N=293)
1.2
5g
(N=76)
2.5g
(N=169)
5.0g
(N=176)
10.0g
(N=187)
Sexdistribution(M:F,
%)
669:625
590:556
539:518
322:2
86
47:53
51:49
57:43
50:50
52:48
49:51
56:44
50:50
50:50
49:51
55:45
48:52
50:50
51:49
60:40
50:50
Meanagerange(days)
96(40198)
161(93431)
227(145
501)
548(454
843)
99(40176)
95(40179)
96(45178)
96(45
198)
165(94431)
160(93308)
162(100395)
160(98405)
230(150480)
225(145414)
230(152
501)
226(154434)
549(459843)
547(459837)
551(454704)
547(463774)
Meanweightrange(kg)
5.5
(3.89.5
)
6.5
(4.111.5
)
7.1
(5.011.5
)
9.3
(6.2
14.0
)
5.3
(3.88.2
)
5.6
(4.08.7
)
5.6
(3.99.4
)
5.5
(3.99.5
)
6.2
(4.18.2
)
6.5
(4.510.3
)
6.6
(4.711.5
)
6.5
(4.810.0
)
6.8
(5.09.9
)
7.1
(511.0
)
7.2
(5.2
11.5
)
7.3
(5.411.0
)
9.4
(7.413.5
)
9.1
(6.213.0
)
9.3
(6.912.7
)
9.2
(6.514.0
) 1.25g group had a significantly higher GMC of filamen-
tous hemagglutinating (FHA) antibodies (6.35) as compared
to the 2.5g (4.83) and 5.0g groups (4.88). Although some
of the above differences in post immunization titers to DTP
antigens were found to be statistically significant, they are
unlikely to be of clinical importance.
With respect to the percent of infants with antibody levelsat or above protective levels ( 0.1 U/ml)after immunization,
serologic results for DPT antigens were similar in all vaccine
groups. The only significant difference seen was a higher
percentage with antibody levels to pertussis toxin0.1 IU/ml
in the infants who received 1.25g Hib than in the other Hib
dosage groups. Protective levels (0.1 IU/ml) were seen in
almost all infants after primary immunization: 98.9100%
for anti-diphtheria toxin; 99.6100% for anti-tetanus toxoid;
7486% for anti-pertussis toxin; 7274% for anti-FHA; and
9798% for B. pertussis agglutinating antibody.
The GMC of antibody to diphtheria toxin in the group
that received 10.0g PRP-T (6.38) was significantly lower
than in those who received 1.25 or 2.5 g (8.68 and 8.37,respectively, p = 0.0154). Additionally, in the 1.25g group,
a higher GMC of anti-pertussis toxin was seen than in the
other three groups, a higher GMC of antibodies against per-
tussis filamentous hemagglutinin (FHA) than in the 2.5 or
10.0g groups, and a higher GMC of anti-tetanus toxoid
than in the 2.5g group.
3.2. Adverse events
During the primary immunization phase, a total of 38
infants were excluded from further participation. Of these
exclusions, 25 were for medical reasons: 14 for febrile con-vulsions; two for rash after vaccination, possibly allergic;
one for brief respiratory difficulty after the first injection (the
child recovered without any sequelae); one for chills 30 min
after the second injection; three for fever 39.5 C after vac-
cination (one after the first dose and three after the third); one
for sterile abscess at the injection site; and three infants were
excluded for unrelated medical problems (colostomy, abnor-
mal head circumference, and tuberculosis). Nine infants were
excluded because they received non-study vaccine, and four
infants were excluded because they erroneously received a
dose not corresponding to their randomization number.
The adverse event data are presented in Table 3. The local
reaction to the injection were mild, with only between 0.6 and
4.6% of parents reported induration of 10 mm or greater at the
injection site, with no significant difference between differ-
ent groups of vaccine dosages or between different injection
number. This generally resolved in a week and nobody expe-
rienced long term sequalae.
For the systemic reactions, the incidence of inconsolable
crying among groups of children that received different vac-
cine dosages was between 1.4 and 5.8%, with no significant
different regarding the incidence of this adverse reaction
between different groups of vaccine dosages or between dif-
ferent injection number.
-
8/3/2019 NIVELES DE ANTICUERPOS
6/10
N.H. Punjabi et al. / Vaccine 24 (2006) 17761785 1781
Table 2
Antibody response to diphtheria, tetanus, and pertussis vaccine components
Antigen g PRP per vaccine dose Baseline 7 Months (after third dose)
GMC %0.1 IU/ml GMC % 1 IU ml %4-fold rise in titer
Diphteria (IU/ml) 1.25 0.13 60 8.68 100 NA
2.5 0.14 56 8.37 100 NA
5 0.14 58 7.69 98.9 NA10 0.13 52 6.38a 99.2 NA
Tetanus (IU/ml) 1.25 1.05 93 22.88 100 NA
2.5 0.91 88 18.15b 100 NA
5 0.87 87 19.55 99.6 NA
10 0.76 85c 20.17 100 NA
Pertussis toxin (g IgG/ml) 1.25 0.58 NA 11.4d NA 86e
2.5 0.60 NA 6.94 NA 74
5 0.59 NA 7.55 NA 74
10 0.64 NA 8.64 NA 76
FHA (g IgG/ml) 1.25 0.63f NA 6.35g NA 73
2.5 0.44 NA 4.83 NA 74
5 0.46 NA 5.34 NA 74
10 0.51 NA 4.88 NA 72
Pertussis 1.25 10.79 NA 481.09 NA 97
Agglutinating 2.5 11.05 NA 505.81 NA 97
Titer 5 10.95 NA 515.28 NA 97
10 10.81 NA 543.60 NA 98
a p < 0.05 vs. dose 2.5g, p = 0.05 vs. dose 1.25g.b p < 0.05 vs. dose 1.25g.c p < 0.05 vs. dose 1.25g.d p < 0.001 vs. dose 2.5g, p < 0.002 vs. dose 5g, p < 0.05 vs. dose 10g.e p < 0.007 vs. dose 2.5g, p < 0.007 vs. dose 5g, p < 0.02 vs. dose 10g.f p < 0.005 vs. dose 2.5g, p < 0.02 vs. dose 5g.g p < 0.05 vs. dose 2.5g, p = 0.05 vs. dose 10g.
Table 3
Adverse events associated with immunization
Adverse event Dose Percent reporting event
1.25g 2.5g 5.0g 10.0g
Fever (38 C) 1 51.6* 38.1 43.1 42.5
2 56.7* 37.2 45.0 35.0
3 38.9** 41.3 35.3 33.4
4 26.3*** 11.8 23.3 17.1
Irritability 1 60.0 56.5 64.3 62.7
2 72.0# 57.0 59.8 64.1
3 75.8$ 62.7 64.1 64.2
4 75.0 65.1 63.6 65.8
Inconsolable crying 1 4.7 4.3 4.9 4.6
2 4.3 3.7 5.1 5.0
3 4.7 5.6 5.8 4.4
4 1.4 2.4 2.3 1.7
Induration (10 mm) 1 4.2 2.7 2.7 3.3
2 3.7 2.7 2.1 4.6
3 1.3 3.0 3.2 3.4
4 1.3 0.6 2.8 2.1
* p < 0.008 vs. 2.5, 5.0, and 10.0g doses.** p < 0.009 vs. 10.0g dose.
*** p < 0.031 vs. all doses.# p < 0.02 vs. 2.5g dose, and p < 0.007 vs. 5.0g.$ p < 0.001 and 0.005 vs. 2.5, 5.0, and 10.0g, respectively.
For irritability after injection, the overall incidence washigh as reported by theparents,between 56.5 and75.8%, with
thegroupthat received theDPT with 1.25gHibaftersecond
and third injection having significantly higher incidence in
comparison to the other groups of DPT with higher dosages
of Hib.
Fever of 38 C or higher was reported among 11.8 and
56.7% of children. Infants who received DTP containing
the 1.25g dose of Hib had the highest proportion of fever
38 C, a difference which was significant for the 1st, 2nd,
and4th immunizationcomparedto allother doses,and signif-
icantly higherthan forthe 5.0and 10.0g doses after thethird
vaccination. Irritability was seen more often among infants
who received the 1.25g dose of Hib as compared to those
in the 2.5, 5.0, and 10.0g groups; this was significant for
the 2nd and 3rd immunization.
There were a total of 40 incidences of febrile seizures:
eight occurred after the first, six after the second, and 26
after the fourth (booster) dose of vaccine; these differences
were statistically not significant, and no seizures resulted in
any permanent sequelae. A total of 15 infants developed a
rash after vaccination, but only two of these were excluded
from further participation.
A total of sixinfants required hospitalization: onefor chills
(described above), two for a respiratory infection which was
-
8/3/2019 NIVELES DE ANTICUERPOS
7/10
1782 N.H. Punjabi et al. / Vaccine 24 (2006) 17761785
notsymptomatic prior to vaccination, andthreefor high fever,
diarrhea, and cough, with onset 28 days after immunization.
There was no significant difference in the rates of hospi-
talization between the vaccine groups.
There were a total of four deaths, but all were consid-
ered unrelated to vaccine administration. Three infants died
at home, having not sought medical care prior to death. One3-month-old died 1 month after the first DTP-Hib 5g vacci-
nation; another infantdied at age6 months, 2 weeks following
the second DTP-Hib 5g vaccination; both were well before
immunization andduringthe 7-day follow-up period; the par-
ents account of the illness did not clarify the probable cause
of death. A third infant died from pneumonia at age 9 months,
4 monthsafter receiving histhird DTP-Hib 2.5g. Thefourth
infant died at age 3 months, about 18 h after his first vaccina-
tion with DTP-Hib 2.5g. He had been healthy and afebrile
prior to vaccination, but developed fever and irritability sev-
eral hours later, refusing to breast-feed. The parents did not
contact the CHW, and he died at home in the early morn-
ing. A post mortem examination was offered but the parentsdeclined.
A total of 162 infants were not brought for the complete
series of primary immunizations, 102 (7.8%) for the second
dose and60 (5%) for the third dose; reasons included families
having left the area (in part due to the economic crisis that
affected Indonesia in the middle of the study).
Adverse events after booster immunization did not dif-
fer among dosage groups, with the exception of DTP with
the 1.25g Hib dose group, in which fever was seen sig-
nificantly more often (26.3%, p < 0.005) than in the other
three groups (12, 23, and 17%). Irritability, induration, and
inconsolable crying were not significantly different amongthe dosage groups.
4. Discussion
The history of infectious diseases and public health have
established the role of vaccination in the prevention of infec-
tious diseases, resulting in dramatic declines or even, as in the
case of small-pox, eradication of disease [13,2125]. This
success story has been repeated with the virtual elimination
of Hib invasive diseases in North American and European
countries following the inclusion of Hib-conjugate vaccines
in national immunization programs [49].
In developing countries, a reluctance to adopt similar
strategies was based on low reported incidences of invasive
Hib diseases, high vaccine costs, and the much higher burden
of other infectious diseases that were more easily diagnosed
[1014]. The incidence has been underestimated because ofdiagnostic difficulties such as the lack of pathognomonic
signs and symptoms, incorrect laboratory procedures, and
avoidance of cultures because of cost or cultural fear of
lumbar puncture [4,5]. Recent studies and improvements in
laboratory diagnosis have shown incidences of Hib inva-
sive diseases that are higher in many developing compared
to industrialized countries, with the exception of epiglottitis
[4].
Despite these data, national immunization programs in
developing countries have not yet adopted Hib vaccine in
their EPI, due to its high cost. Strategies to make the vac-
cine affordable include the use of combined vaccines, multi
dose presentation, or incorporation of lower antigen doses[4,1618].
This study demonstrates that one-eighth of the standard
10g dose of PRP-T elicits protective antibody levels, with
99.6% of infants developing antibody levels of0.15g/ml
and 96.4% of1.0g/ml, levels which correlate with short-
and long-term protection, respectively. These results are com-
parable to standard dosage Hib conjugate vaccines and are
comparable to the results obtained in Chile by Lagos et al.
[26]. In addition, these lower dose Hib-DTP vaccines elicited
antibody levels against the DTP antigens equivalent to stan-
dard dose vaccine (Table 4).
The hospitalizations and adverse events observed wereevenly distributed among all the groups. The four deaths
observed during the 3.5-year study duration can be extrap-
olated to an annual infant mortality rate (IMR) of slightly
more than one per 1000. In comparison, the annual IMR is
43/1000 for Indonesia, and 27/1000 for the Jakarta province,
indicating a favorable effect of participation in the vaccine
study, and of regular medical care, in comparison to the
general infant population [27]. It would be safe to assume
that if the infants who died had been taken to the hospital in
a timely fashion, some or all of the deaths could have been
prevented. Three of the four infants were doing well on day 7
Table 4
Anti-PRP antibody response following immunization with DPT-PRP-T vaccines
g PRP/dose Geometric mean anti-PRP (g/ml) Total (%)
Baseline Post-immunization 0.15g/ml 1g/ml
Baseline Post-immunization Baseline Post-immunization
1.25g 0.12* 12.48 32** 100 8 96.4
2.5g 0.16 15.62 41 99.6 11 97.4
5.0g 0.15 17.28 45 99.6 7 98.2
10.0g 0.14 15.10 43 99.6 7 96.9
* p < 0.02 for comparison with dose 5.0g.** p < 0.05 for comparison with doses 5.0g and 10.0g.
-
8/3/2019 NIVELES DE ANTICUERPOS
8/10
N.H. Punjabi et al. / Vaccine 24 (2006) 17761785 1783
after vaccination, so it is very unlikely that these deaths were
related to vaccination. The fourth death occurred within 24 h
after vaccination; the relationship between this death and
vaccination remained unclear.
Many publications have confirmed Hib vaccine to be
one of the safest vaccines ever used, whether alone or in
combination, in a standard or in a reduced dose [2835].Similar observations have been made regarding diphtheria
and tetanus vaccines. The side effects of DTP combined
with conjugated Hib vaccines are similar to those seen
after DTP alone, and were most likely attributable to the
killed whole cell pertussis component [27]. In the compar-
ison of placebo versus Hib added to whole cell DTP vac-
cine, no significant increase in adverse reactions was found
[36].
Killed whole cell pertussis vaccine is known to cause
significant adverse reactions, including neurological side
effects such as seizures. The latter events have been consid-
ered acceptable because of the effectiveness and low cost
of whole-cell pertussis vaccine, as described by Edwardsand Decker in their editorial concerning two acellular vac-
cine trials [3740]. The decline in the use of whole cell
killed pertussis vaccine in the 1970s in Japan, Sweden, and
United Kingdom was followed by a resurgence of pertus-
sis cases and then the development of the acellular vaccine
[39,41,42]. Many countries continue to use whole cell killed
pertussis vaccine in their immunization programs, a policy
that is supported by the World Health Organization (Global
Programme for Vaccine and Immunization, Expanded Pro-
gramme on Immunization (EPI), 1996) [43]. This policy is
also maintained by the Indonesian National Immunization
Program and by Immunization Authorities in other countries[4447].
The killed whole cell pertussis vaccine was incorporated
into the vaccine used for this trial because of the adjuvant
effect that it provides for the PRP-Hib antigen. Less satis-
factory immune responses to Hib antigens are seen when
it is combined with the acellular pertussis vaccine [48]. In
developing countries with high infant mortality rates, pneu-
monia is the leading cause of death. In developed countries,
Streptococcus pneumoniae and Haemophilus influenzae are
the principal pathogens in bacterial pneumonia [1]. Another
study comparing DTP-Hib with DTP, conductedon the island
of Lombok in Indonesia, to evaluate the incidence of vaccine-
preventable Haemophilus influenzae type b pneumonia and
meningitis, observed 1449 deaths or 2.6% among 55,073
children enrolled, with 77% of all deaths occurring else-
where than in hospital [49]. The difference between this and
our study was that the Lombok study areas were more rural
regarding the population and the availability of health care
facilities.
In conclusion, reduced doses of Hib PRP-T combined
with killed whole cell pertussis DTP vaccine, when used for
primary immunization, produce immune responses and side
effects that are comparable to those observed after admin-
istration of the 10g PRP-Hib-DTP combination. DTP-Hib
vaccines containing 5, 2.5, or 1.25 g of PRP-Hib could be
affordable for developing countries, and would be expected
to reduce infant and childhood morbidity and mortality if
included in their EPI programs.
Berna Biotech Ltd., Berne, Switzerland, does not manu-
facture DTP or Hib vaccines any more.
Acknowledgements
This study was supported by grant from the Berna Biotech
Ltd. (formerly known as Swiss Serum and Vaccine Institute),
Berne, Switzerland, by the Indonesian Ministry of Health,
and by the U.S. Naval Medical Research and Development
Command, Navy Department.
For their support and encouragement for the study, the
authors would like to thank the Director and staff of National
Institute of Health Research and Development (NIHRD or
Badan Penelitian dan Pengembangan Kesehatan Departe-
men Kesehatan) R.I., Ministry of Health of Indonesia, thestaff of the Bacteriology Laboratory, Center for Infectious
Diseases Research NIHRD RI, the Commanding Officer and
personnel of U.S. Naval Medical Research Unit (NAMRU)
No. 2, Jakarta, Indonesia, the Directors, medical and nursing
staffs of the PUSKESMAS Cibinong, Cirimekar, Citeureup
and Gunung Putri in Kab. Bogor and PUSKESMAS Kapuk,
Penjaringan, Koja and Sunter Agung in North Jakarata, the
Directors and staff of the Infectious Diseases Hospital Prof.
Dr. Sulianti Saroso of Jakarta, Atmajaya Hospital, Koja and
Bhakti Husada Hospitals, DR Yulitasari and Drs. Maya, Mar-
taria Dhiana, Shinta Laurencia, Nurmiati Nasution, Cynthia,
Robert Polowidjaja and Mr. Maman Supriatman for theirassistance in the study implementation.
References
[1] Shann F, Steinhoff MC. Vaccines for children in rich and poor coun-
tries. Lancet 1999;354:711.
[2] Arya SC. Human immunization in developing countries: practical
and theoritical problems and prospects. Vaccine 1994;12:142335.
[3] Bart KJ, Lin KFYC. Vaccine-preventable disease and immunization
in the developing world. Ped Clin N Am 1990;37:73555.
[4] Peltola H. Worldwide Haemophilus influenzae type b disease at the
beginning of the 21st century: global analysis of the disease bur-
den 25 years after the use of the polysaccharide vaccine and adecade after the advent of conjugates. Clin Microbiol Rev 2000;13:
30217.
[5] Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Stat
M, et al. Decline of childhood Haemophilus influenzae type b
(Hib) disease since introduction of vaccination. JAMA 1993;269:
2468.
[6] Peltola H. Haemophilus influenzae type b disease and vaccination in
Europe: lesson learned. Pediatr Infect Dis J 1998;17:S12632.
[7] Wenger D. Epidemiology of Haemophilus influenzae type b disease
and impact of Haemophilus influenzae type b conjugate vaccine in
the United States and Canada. Pediatr Infect Dis J 1998;17:S1326.
[8] Eskola J, Takala AK, Katyhty H, Peltola H, Makela PH. Experience
in Findland with Haemophilus influenzae type b vaccines. Vaccine
1993;9:S5146.
-
8/3/2019 NIVELES DE ANTICUERPOS
9/10
1784 N.H. Punjabi et al. / Vaccine 24 (2006) 17761785
[9] Barbour ML, Booy R, Cook DW, Griffiths H, Chapel HM,
Moxon ER, et al. Haemophilus influenzae type b carriage and
immunity four years after receiving the Haemophilus influen-
zae oligosaccharide-CRM197(HbOC)conjugate vaccine. Pediatr Infect
Dis J 1993;12:47884.
[10] Munson Jr RS, Kabeer MH, Lenoir AA, Granoff DM. Epidemiol-
ogy and prospects for prevention of disease due to Haemophilus
influenzae in developing countries. Rev Infect Dis 1989;11(S3):
S58897.
[11] Peltola H. Spectrum and burden of severe Haemophilus influenzae
type b disease in Asia. Bull WHO 1999;77:87887.
[12] Punjabi ML. Typhoid fever: a continuing health problem for pediatric
population in developing countries. In: Ou JT, Chiu CH, Chu CS,
editors. Typhoid fever and other salmonellosis. Taipei, ROC: Jeou
Chou Book Co.; 2001. p. 2549.
[13] Salisbury DM. Summary statements: The First International Confer-
ence on Haemophilus influenzae type b in Asia. Pediatr Infect Dis
J 1998;17:S935.
[14] Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A,
Omosigho C, et al. Randomized trial of Haemophilus influenzae type
b tetanus protein conjugate for prevention of pneumonia and menin-
gitis in Gambian infants. Lancet 1997;349:11917.
[15] Dagan R, Fraser D, Greif Z, Keller N, Kaufstein M, ShasbergG, et al. Isreali pediatric bacteremia and meningitis group. A
nationwide prospective surveillance study in Israel to document
pediatric invasive infections, with an emphasis on Haemophilus
influenzae type b infections. Pediatr Infect Dis J 1998;17:S198
203.
[16] Miller M. An assessment of the value of Haemophilus influenzae
type b conjugate vaccine in Asia. Pediatr Infect Dis J 1998;17:
S1529.
[17] Huebner RE, Nicol M, Mothupi R, Kayhty H, Mbelle N, Khomo
E, et al. Dose response of CRM197 and tetanus toxoid conju-
gated Haemophilias influenzae type b vaccines. Vaccine 2004;23:
8026.
[18] Tamm E, Veronese A, Contorni M, Meriste S, Nacci P, Viviani
S. Duble-blind study comparing the immunogenicity of a licensed
DtwPHib-CRM 197 conjugate vaccine (Quattvaxem
TM
) with threeinvestigational, liquid formulations using lower doses of Hib-
CRM197 conjugate. Vaccine 2005;23:17159.
[19] Richie E, Punjabi NH, Harjanto SJ, Wangsasaputra F, Sukandar
M, Suptriatman M, et al. Safety and immunogenicity of combined
diphtheriatetanuspertussis (whole cell and acellular)Haemophilus
influenzae type b conjugate vaccine administered to Indonesian chil-
dren. Vaccine 1999;17:138493.
[20] Panpitpat CH, Thisyakorn U, Chotpitayasunondh T, Furer E, Que
JU, Hasler T, et al. Elevated levels of maternal anti-tetanus toxin
antibodies do not suppress the immune response to a Haemophilus
influenzae type b PRP-tetanus toxoid conjugate vaccine. Bull WHO
2000;78:36471.
[21] Plotkin SL, Plotkin SA. Short history of vaccination. In: Plotkin SA,
Orenstein WA, editors. Vaccine. 3rd ed. Philadelphia: WB Saunders;
1999. p. 112.[22] NIAID International Centers for Tropical Disease Research. Death
and disease in the majority world. Key to recognition and prevention.
Vaccine for tropical diseases. Report of the second annual meeting,
April 2830, 1993. p. 1324.
[23] Ernst JD. Toward the development of antibacterial vaccines: report
of a symposium and workshop. Clin Infect Dis 1999;29:1295
302.
[24] Marchant A, Newport M. Prevention of infectious diseases by neona-
tal and early infantile immunization: prospects for the new mille-
nium. Curr Opin Infect Dis 2000;13:2416.
[25] Kane MA. Commentary: public perception and the safety of immu-
nization. Vaccine 1998;16:S735.
[26] Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo
A, Wasserman SS, et al. Economisation of vaccination against
Haemophilus influenzae type b: a randomized trial of immuno-
genicity of fractional-dose and two-dose regimens. Lancet 1998;351:
14726.
[27] Central Bureau of Statistics and Indonesian Ministry of Health.
Demographic Health Surveys, Indonesian EVIR. September 1998.
p. 183221.
[28] Ward JI, Zangwill. Haemophilus influenzae vaccines. In: Plotkin SA,
Orenstein WA, editors. Vaccine. 3rd ed. Philadelphia: WB Saunders;
1999. p. 183221.
[29] Fritzell B, Plotkin SA. Efficacy and safety of a Haemophilus influen-
zae type b capsular polysaccharidetetanus protein conjugate vac-
cine. J Pediatr 1992;121:35562.
[30] Pickering LK, Peter G, Baker CJ, Gerber Ma, MacDonald NA,
Orenstein WA, et al. Haemophilus influenzae infections. American
Academy of Pediatrics. In: 2000 Red book: report of the Committee
on Infectious Diseases, 25th ed. 2000. p. 262272.
[31] Begg NT, Miller EM, Fairley CK, Chapel HM, Griffiths H, Waight
PA, et al. Antibody responses and symptoms after DTP and either
tetanus or diphtheria Haemophilus influenzae type B conjugate vac-
cines given for primary immunization by separate or mixed injection.
Vaccine 1995;134:154750.
[32] Ferreccio C, Clemens J, Avenando A, Horwitz I, Flores C, Avila L,
et al. The clinical and immunological responses of Chilean infants to Haemophilus influenzae type b polysaccharidetetanus protein con-
jugate vaccine in the same syringe with diphtheriatetanus toxoids-
pertussis vaccine at two, four and six months of age. Pediatr Infect
Dis J 1991;10:76471.
[33] Claesson BA, Schneerson R, Lagergard T, Trollfors B, Taranger
J, Johansson J, et al. Persistence of serum antibodies elicited by
Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in
infants vaccinated at 3, 5 and 12 months of age. Pediatr Infect Dis
J 1991;10:5604.
[34] Chotpitayasunondh T, Panpitpat C, Thisyakorn U, Furer E, Que
JU, Hasler T, et al. Safety and immunogenicity of a Haemophilus
influenzae type b polysaccharidetetanus toxoid conjugate vac-
cine combined with diphtheria, tetanus and pertussis vaccines in
Thai infants. Southeast Asian J Trop Med Public Health 1997;28:
918.[35] Decker DD, Edwards KM. Haemophilus influenzae type b vac-
cine: history, choice and comparisons. Pediatr Infect Dis J 1998;17:
S1136.
[36] Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR.
Nature and rates of adverse reactions associated with DTP and
DT immunizations in infants and children. Pediatrics 1981;68:650
60.
[37] Edwards K, Decker MD, Mortimer Jr EA. Pertussis vaccine. In:
Plotkin SA, Orenstein WA, editors. Vaccine. 3rd ed. Philadelphia:
WB Saunders; 1999. p. 293344.
[38] Edwards KM, Decker MD. Acellular pertussis vaccines for infants.
New Engl J Med 1996;334:3912.
[39] Gangarosa EJ, Galazka AM, Wolfe CR, Philips LM, Gangarosa RE,
Miller E, et al. Impact of anti-vaccine movements on pertussis con-
trol: the untold story. Lancet 1998;351:35661.[40] Miller DS, Wadsworth MJH, Ross EM. Pertussis vaccine and severe
acute neurological illnesses. Response to a recent review by members
of the NCES team. Vaccine 1989;7:4879.
[41] Kimura M, Hikino N. Results with a new DTP vaccine in Japan.
Dev Biol Stand 1985;61:54561.
[42] Storsaeter J, Olin P. Relative efficacy of two acellular pertussis
vaccines during three years of passive surveillance. Vaccine 1992;
10:1424.
[43] WHO. Global Programme for Vaccine and Immunization, Expanded
Programme on Immunization. Immunization policy. WHO/EPI/
GEN/95.03.REV1, 1996.
[44] Prijanto M. Penetapan standar nasional dari vaksin DPT. Penetapan
standar nasional dari vaksin Pertussis. Bull Health Studies Indonesia
1982;10:810.
-
8/3/2019 NIVELES DE ANTICUERPOS
10/10
N.H. Punjabi et al. / Vaccine 24 (2006) 17761785 1785
[45] Sub Directorate of immunization, Indonesian CDC, Indonesian
MOH. National Policy for immunization/Petunjuk Pelaksanaan Pro-
gram Imunisasi, 3rd ed., 1993.
[46] Fletcher MA, Saliou P, Ethevanoux C, Plotkin SA. The efficacy
of whole-cell pertussis immunization: collected data on a vaccine
produced in France. Public Health 2001;115(2):11929.
[47] Conseil superieur dhygiene publique de France. Calendrial vaccinal
1998. Bull Epidemiol Hebdomadaire 1999;15:612.
[48] Decker MD, Edwards K. Combination vaccines. In: Plotkin SA,
Orenstein WA, editors. Vaccine. 3rd ed. Philadelphia: WB Saunders;
1999. p. 50830.
[49] Gessner BD, Sutanto A, Linehan M, Djelantik IG, Fletcher
T, Gerudug IK, et al. Incidences of vaccine- preventable
Haemophilus influenzae type b pneumonia and meningitis in
Indonesian children: hamlet-randomised vaccine-probe trial. Lancet
2005;365(9453):4352.